HEIDELBERG

Heidelberg Materials North America Announces Latest Step in Edmonton CCUS Project

Retrieved on: 
Thursday, February 15, 2024

Irving, Texas, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Heidelberg Materials North America announced today a significant milestone in its two-stage competitive procurement process as it works to select the capture technology and contractor for providing the CO2 separation solution for its Edmonton, Alberta, Carbon Capture, Utilization, and Storage (CCUS) Project.

Key Points: 
  • Irving, Texas, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Heidelberg Materials North America announced today a significant milestone in its two-stage competitive procurement process as it works to select the capture technology and contractor for providing the CO2 separation solution for its Edmonton, Alberta, Carbon Capture, Utilization, and Storage (CCUS) Project.
  • This ground-breaking project will be the first full-scale application of CCUS in the cement sector.
  • “We are excited to take this latest step in our journey to produce the world’s first net-zero cement,” said Joerg Nixdorf, Vice President Cement Operations, Northwest Region for Heidelberg Materials North America.
  • “With each milestone we come closer to realizing our vision of leading the decarbonization of the cement industry.”
    “We are pleased to have been selected by Heidelberg Materials North America to provide the FEED of this groundbreaking project in Canada,” said Christophe Malaurie, SVP Decarbonization Solutions for Technip Energies.

Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X

Retrieved on: 
Tuesday, January 9, 2024

OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.

Key Points: 
  • OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
  • For details, please refer to the following BioMed X press release and application guidelines for the research project:
    BioMed X's press release dated December 19, 2023:

Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X

Retrieved on: 
Tuesday, January 9, 2024

OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.

Key Points: 
  • OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
  • For details, please refer to the following BioMed X press release and application guidelines for the research project:
    BioMed X's press release dated December 19, 2023:

EQS-News: Planned Silumina Anodes plant focusing on nanocoated silicon achieves an increase in annual output capacity from 15 GWh to 120 GWh in terms of equivalent battery capacity

Retrieved on: 
Saturday, December 30, 2023

With an anode mixing ratio of 10/90 at the battery manufacturer, a battery capacity of approx.

Key Points: 
  • With an anode mixing ratio of 10/90 at the battery manufacturer, a battery capacity of approx.
  • The plant is now designed for the production of alumina-coated metallurgical silicon with an annual output of 8,000 t/y.
  • This product will be integrated into the anode graphite by the customers in their battery factories and not in the Altech plant.
  • This change in production strategy significantly increases the equivalent battery capacity of Altech's active anode material Silumina Anodes from 15 GWh to 120 GWh per year.

Heidelberg Materials North America’s Edmonton & Delta Cement Plants Receive ENERGY STAR Certification

Retrieved on: 
Thursday, December 21, 2023

Irving, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Heidelberg Materials North America announced today that its cement plants in Edmonton, Alberta, and Delta, British Columbia, have earned Natural Resources Canada’s (NRCan’s) ENERGY STAR for Industry Certification, which signifies that the facility performs in the top quartile of similar facilities in Canada and the United States for energy efficiency.

Key Points: 
  • Irving, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Heidelberg Materials North America announced today that its cement plants in Edmonton, Alberta, and Delta, British Columbia, have earned Natural Resources Canada’s (NRCan’s) ENERGY STAR for Industry Certification, which signifies that the facility performs in the top quartile of similar facilities in Canada and the United States for energy efficiency.
  • "We are pleased to accept the ENERGY STAR for Industry Certification in recognition of our energy efficiency efforts at our Edmonton and Delta cement plants in Canada,” said Oliver Patsch, President of Heidelberg Materials North America’s Northwest Region.
  • It is also reflective of Heidelberg Materials’ efforts to improve its energy performance by managing energy strategically across the entire organization.
  • Heidelberg Materials North America has operational efficiency and energy optimization programs in place across all its business lines and the company strives to continually improve its performance in these areas.

Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board

Retrieved on: 
Thursday, December 7, 2023

and STEVENAGE, United Kingdom, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Gunnar Voss von Dahlen (54) has been appointed as Chief Financial Officer, effective December 1, 2023.

Key Points: 
  • and STEVENAGE, United Kingdom, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Gunnar Voss von Dahlen (54) has been appointed as Chief Financial Officer, effective December 1, 2023.
  • Gunnar Voss von Dahlen succeeds Alexander Dettmer, who left the company in best mutual agreement in October 2023, as agreed with the Supervisory Board.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: “On behalf of the entire Supervisory Board, I am pleased to welcome Gunnar Voss von Dahlen as our new CFO.
  • Mr. Voss von Dahlen is an experienced financial expert with a successful track record in various companies and industries.

Heidelberg Materials North America Offers Free On-Demand Concrete Sustainability Course

Retrieved on: 
Wednesday, December 6, 2023

The course focuses on the environmental impact of carbon emissions related to concrete, including a basic overview of the material science that goes into concrete mixtures.

Key Points: 
  • The course focuses on the environmental impact of carbon emissions related to concrete, including a basic overview of the material science that goes into concrete mixtures.
  • Defining the meaning of the term “supplementary cementitious materials” and how it relates to reducing the carbon footprint of concrete.
  • “Mastering Sustainable Concrete: on the Road to Net Zero Construction” is part of a multifaceted effort on the part of Heidelberg Materials to be a leader in decarbonizing the concrete industry.
  • Heidelberg Materials educates its employees in sustainability through structured training programs that develop and empower personnel.

EQS-News: PRECISIS GmbH celebrates Win at the Innovation Award of the Federal State Baden-Württemberg 2023

Retrieved on: 
Thursday, December 14, 2023

Heidelberg, November 22nd 2023* — We are overjoyed to announce that PRECISIS GmbH has been not only nominated but has secured victory in the prestigious Innovation Award of the Federal State Baden-Württemberg 2023 on 21st of November 2023.

Key Points: 
  • Heidelberg, November 22nd 2023* — We are overjoyed to announce that PRECISIS GmbH has been not only nominated but has secured victory in the prestigious Innovation Award of the Federal State Baden-Württemberg 2023 on 21st of November 2023.
  • This recognition fills us with immense pride and reinforces our dedication to pushing the boundaries of medical technology.
  • This unique stimulator is implanted directly under the scalp, allowing precise brain stimulation without any physical contact with the brain.
  • Winning in the Innovation Award of the Federal State Baden-Württemberg 2023 is a tremendous honor for us.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
Thursday, December 14, 2023

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.

EQS-News: Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board

Retrieved on: 
Wednesday, December 13, 2023

Laupheim, Milford, MA, USA, and Stevenage, UK, December 07, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Gunnar Voss von Dahlen (54) has been appointed as Chief Financial Officer, effective December 1, 2023.

Key Points: 
  • Laupheim, Milford, MA, USA, and Stevenage, UK, December 07, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Gunnar Voss von Dahlen (54) has been appointed as Chief Financial Officer, effective December 1, 2023.
  • Gunnar Voss von Dahlen succeeds Alexander Dettmer, who left the company in best mutual agreement in October 2023, as agreed with the Supervisory Board.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: “On behalf of the entire Supervisory Board, I am pleased to welcome Gunnar Voss von Dahlen as our new CFO.
  • Mr. Voss von Dahlen is an experienced financial expert with a successful track record in various companies and industries.